Vaccines against cholera, typhoid fever and shigellosis for developing countries

Bibliography

• WHO: Cholera 2002. Wkly Epidenhol Rec. (2003) 78:269–276.
   Google Scholar
• •Source for annual updates on cholera from the WHO.
   Google Scholar
• SACK DA, SACK RB, NAIR GB,SIDDIQUE AK: Cholera. Lancet (2004) 363(9404)223–233.
   Google Scholar
• ••A comprehensive review of cholera.
   Google Scholar
• WHO: Cholera vaccines: a new publichealth tool? (2002) Geneva, Switzerland.
   Google Scholar
• ••A recent document from the WHO withupdated recommendations on the use of cholera vaccines.
   Google Scholar
• HOLMGREN J, BERGQUIST C: Oral B subunit killed whole-cell cholera vaccine. In: New Generation Vaccines. Levine MM, Kaper JB, Liu MA, Rappuoli R, Good MF (Eds), Marcel Dekker, NY, USA (2004):499–510.
   Google Scholar
• ••A detailed source of information on killedoral cholera vaccines and mechanism of protection against disease.
   Google Scholar
• MOSLEY WH: The role of immunity in cholera. A review of epidemiological and serological studies. Tex. Rep. Biol. Med. (1969) 27\(Suppl. 1):227–241.
   Google Scholar
• FINKELSTEIN RA: Vibriocidal antibody inhibition (VAT) analysis: a technique for theidentification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. Immunol. (1962) 89:264–271.
   Web of Science ®Google Scholar
• LEVINE MM, NALIN DR, CRAIG JP et al.: Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg. (1979) 73(1):3–9.
   PubMed Web of Science ®Google Scholar
• KOSSACZKA Z, SHILOACH J, JOHNSON V et al.: Vibrio cholerae 0139 conjugate vaccines: synthesis and immunogenicity of V cholerae 0139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Inman. (2000) 68(9):5037–5043.
   PubMed Web of Science ®Google Scholar
• CLEMENS JD, SACK DA, HARRIS JR et al.: Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet (1990) 335 (8684):270–273.
   PubMed Web of Science ®Google Scholar
• •A large-scale, randomised, controlled trial of the Swedish cholera vaccine in Bangladesh demonstrating efficacy.
   Google Scholar
• SANCHEZ JL, VASQUEZ B, BEGUE RE et al.: Protective efficacy of oral whole-cell/ recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 344(8932):1273–1276.
   PubMed Web of Science ®Google Scholar
• •A randomised controlled trial that confirmed efficacy of the Swedish cholera vaccine in a Latin American population.
   Google Scholar
• CLEMENS JD, STANTON BF,CHAKRABORTY J et al.: B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. .1 Infect. Dis. (1987) 155(1):79–85.
   Google Scholar
• •A study of the safety and immunogenicity of the Swedish oral cholera vaccine in Bangladesh.
   Google Scholar
• ERIKSSON K, KILANDER A, HAGBERG L, NORKRANS G, HOLMGREN J, CZERKINSKY C: Intestinal immune responsiveness in HIV-infected individuals. Adv. Exp. Med. Biol. (1995) 371B:1011–1014.
   PubMedGoogle Scholar
• ORTIGAO-DE-SAMPAIO MB, SHATTOCK RJ, HAYES P et al: Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS (1998) 12(14):F145–F150.
   PubMed Web of Science ®Google Scholar
• LEWIS DJ, GILKS CF, 0J00 S et al.: Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS (1994) 8(6):779–785.
   Google Scholar
• TRACH DD, CLEMENS JD, KE NT et al.: Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 349(9047):231–235.
   PubMed Web of Science ®Google Scholar
• •An efficacy trial of the Vietnamese oral cholera vaccine.
   Google Scholar
• TRACH DD, CAM PD, KENT et al.:Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bull. World Health Organ. (2002) 80(1):2–8.A study showing equivalence in safety and immunogenicity between the Swedish and Vietnamese killed oral cholera vaccine in adults and children.
   Google Scholar
• LEVINE MM, KAPER JB, HERRINGTON D et al.: Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (1988) 2(8609):467–470.
   PubMed Web of Science ®Google Scholar
• KAPERJB, TACKET CO: Attenuated Vibrio cholerae strains as live oral cholera vaccines and vectors. In: New Generation Vaccines. Levine MM, Kaper JB,Rappuoli R, Liu MA, Good MF (Eds), Marcel Dekker, NY, USA (2004):511–517.
   Google Scholar
• ••A detailed source of information on thelive oral cholera vaccines.
   Google Scholar
• PERRY RT, PLOWE CV, KOUMARE B et al.: A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull. World Health Organ. (1998) 76(1):63–71.
   PubMed Web of Science ®Google Scholar
• •An evaluation of CVD 103-HgR among HIV-infected individuals.
   Google Scholar
• RICHIE EE, PUNJABI NH,SIDHARTA YY et al.: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine (2000) 18(22):2399–2410.
   Google Scholar
• •A randomised controlled trial showing poor protective efficacy of CVD 103-HgR in Indonesia.
   Google Scholar
• CALAIN P, CHAINE JP, JOHNSON Eet al.: Can oral cholera vaccination play arole in controlling a cholera outbreak? Vaccine (2004) 22(19):2444–2451.
   Google Scholar
• •A non-randomised study of CVD 103-HgR in Micronesia.
   Google Scholar
• COHEN MB, GIANNELLA RA, BEAN Jet al.: Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun. (2002) 70(4):1965–1970.
   Google Scholar
• •A study showing safety, immunogenicity and protection against experimental challenge with V cholerae 01 conferred by Peru-15 in North American volunteers.
   Google Scholar
• TAYLOR DN, SANCHEZ JL, CASTRO JM et al: Expanded safety and immunogenicity of a bivalent, oral,attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.Infect. Immun. (1999) 67(4):2030–2034.
   Google Scholar
• TAYLOR DN, TACKET CO, LOSONSKY G et al: Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun. (1997) 65(9):3852–3856.
   PubMed Web of Science ®Google Scholar
• TACKET CO, KOTLOFF KL, LOSONSKY G et al.: Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae 01 vaccine strain CVD 111. Am. J. Trop. Med. Hyg. (1997) 56(5):533–537.
   PubMed Web of Science ®Google Scholar
• VALLE E, LEDON T, CEDRE B et al.: Construction and characterization of a nonproliferative El Tor cholera vaccine candidate derived from strain 638. Infect. Immun. (2000) 68(11):6411–6418.
   PubMed Web of Science ®Google Scholar
• BENITEZ JA, GARCIA L, SILVA A et al.: Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate. Infect. Immun. (1999) 67(2):539–545.
   PubMed Web of Science ®Google Scholar
• CRUMP JA, LUBY SP, MINTZ ED: The global burden of typhoid fever. Bull. World Health Organ. (2004) 82(5):346–352.
   PubMed Web of Science ®Google Scholar
• ••Recent estimates on typhoid fever burdenof disease.
   Google Scholar
• EDELMAN R, LEVINE MM: Summary of an international workshop on typhoid fever. Rev. Infect. Dis. (1986) 8:329–349.
   PubMedGoogle Scholar
• SINHA A, SAZAWAL S, KUMAR R et al: Typhoid fever in children aged less than 5 years. Lancet (1999) 354(9180):734–737.
   PubMed Web of Science ®Google Scholar
• •Community-based typhoid fever surveillance showing high incidence of typhoid fever in children aged 5 years.
   Google Scholar
• SAHA SK, BAQUI AH, HANIF M et al: Typhoid fever in Bangladesh: implications for vaccination policy. Pediatc Infect. Dis. (2001) 20(5):521–524.
   PubMed Web of Science ®Google Scholar
• WAIN J, KIDGELL C: The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans. R. Soc. Bop. Med. Hyg. (2004) 98:423–430.
   PubMed Web of Science ®Google Scholar
• •A thorough review of worldwide S. Typhi MDR.
   Google Scholar
• PARRY C: The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Vietnam. Trans. R. Soc. Bop. Med. Hyg. (2004) 98:413–422.
   PubMed Web of Science ®Google Scholar
• BAHL R, SINHA A, POULOS C et al: Costs-of-illness of typhoid fever in Indianurban slum community: implications for vaccination policy. I Health Pop]] Nutr. (2004) (In Press).
   Google Scholar
• •First community-based data on typhoid fever cost of illness.
   Google Scholar
• WHO: Background document: the diagnosis, treatment and prevention of typhoid fever. (2003) WHON&B/03.07.
   Google Scholar
• ••A detailed WHO document ontyphoid fever.
   Google Scholar
• KIDGELL C, REICHARD U, WAIN J et al.: Salmonella typhl the causative agent of typhoid fever, is approximately 50,000 years old. Infect Genet Evol (2002) 2:39–45.
   PubMed Web of Science ®Google Scholar
• LEVINE MM: Typhoid fever vaccines. In: Vaccines (3rd ed). Plotkin SA, Orenstein WA (Eds), WB Saunders Co., Philadelphia, PA, USA (1999).
   Google Scholar
• ••A thorough review of typhoidfever vaccines.
   Google Scholar
• PASETTI ME LEVINE MM,SZTEIN MB: Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine (2003) 21(5–6)401–418.
   Google Scholar
• KLUGMAN KP, KOORNHOF HJ, ROBBINS JB, LE CAM NN: Immunogenicity, efficacy and serological correlate of protection of Salmonella Ophi Vi capsular polysaccharide vaccine three years after immunization. Vaccine (1996) 14(5):435–438.
   PubMed Web of Science ®Google Scholar
• •First evidence of 3-year efficacy of the Vi polysaccharide vaccine.
   Google Scholar
• MASTROENI P, MENAGER N: Development of acquired immunity to Salmonella.' Med. Microbiol (2003) 52\(Pt 6):453–459.
   Google Scholar
• KANTELE A: Antibody-secreting cells inthe evaluation of the immunogenicity of an oral vaccine. Vaccine (1990) 8(4):321–326.
   PubMed Web of Science ®Google Scholar
• IVANOFF B, LEVINE MM,LAMBERT PH: Vaccination against typhoid fever: present status. Bull. WorldHealth Organ. (1994) 72(6):957–971.
   PubMed Web of Science ®Google Scholar
• BODHIDATTA L, TAYLOR DN, THISYAKORN U, ECHEVERRIA P: Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect. Dis. (1987) 9(4):841–845.
   PubMedGoogle Scholar
• IMMUNIZATION ACTION COALITION: Vaccines and biologicals used in US and foreign markets. (2003) P5120. St. Paul, MN, USA.
   Google Scholar
• FELIX A, PITT R: A new antigen of B. typhosus. Lancet (1934) 2:186–191.
   Google Scholar
• ROBBINS JD, ROBBINS JB:Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi I Infect. Dis. (1984) 150(3):436–449.
   Google Scholar
• ACHARYA IL, LOWE CU, THAPA R et al: Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi A preliminary report. N Engl. J. Med. (1987) 317(18):1101–1104.
   PubMed Web of Science ®Google Scholar
• •First randomised controlled trial with the Vi polysaccharide vaccine.
   Google Scholar
• KLUGMAN KP, GILBERTSON IT, KOORNHOF HI et al.: Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet (1987) 2(8569):1165–1169.
   PubMed Web of Science ®Google Scholar
• •Randomised controlled trial with Vi polysaccharide.
   Google Scholar
• WANG ZG, ZHOU WZ, SHI J: Efficacyand side effects following immunization with Salmonella OphiV i capsular polysaccharide vaccine. Zhonghua Liu Xing Bing Xue Za Zhi (1997) 18(1):26–29.
   PubMedGoogle Scholar
• •Randomised controlled trial with Chinese Vi polysaccharide.
   Google Scholar
• YANG HH, WU CG, XIE GZ et al:Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull. World Health Organ. (2001) 79(7):625–631.
   PubMed Web of Science ®Google Scholar
• •Randomised controlled trial with Chinese Vi polysaccharide.
   Google Scholar
• HESSEL L, DEBOIS H, FLETCHER M, DUMAS R: Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur. Clin. Microbiol Infect. Dis. (1999) 18(9)609–620.
   Google Scholar
• WORLD HEALTH ORGANIZATION EXPERT COMMITTEE ON BIOLOGIC STANDARDIZATION: Requirements on Vi polysaccharide for typhoid. World Health Organ. Tech. Rep. Ser. (1993) 840:14–32.
   Google Scholar
• MCGHEE JR, MESTECKY J, DERTZBAUGH MT, ELDRIDGE JH, HIRASAWA M, KIYONO H: The mucosal immune system: from fundamental concepts to vaccine development. Vaccine (1992) 10:75–88.
   PubMed Web of Science ®Google Scholar
• DUPONT HL, HORNICK RB, SNYDER MJ, DAWKINS AT,HEINER GG, WOODWARD TE: Studies of immunity in typhoid fever. Protection induced by killed oral antigens or byprimary infection. Bull. World Health Organ. (1971) 44:667–672.
   PubMedGoogle Scholar
• CHUTTANI CS, PRAKASH K, VERGESE A, GUPTA P, CHAWLA RK, GROVER V: Ineffectiveness of an oral killed typhoid vaccine in a field trial. Bull. World Health Organ. (2004) 48:754–755.
   Google Scholar
• CHATFIELD S, ROBERTS M,LONDONO P, CROPLEY I, DOUCE G, DOUGAN G: The development of oral vaccines based on live attenuated Salmonella strains. FEMS Immunol Med. Microbiol (1993) 7:1–7.
   PubMed Web of Science ®Google Scholar
• GERMANIER R, FUER E: Isolation andcharacterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. (1975) 131(5):553–558.
   PubMed Web of Science ®Google Scholar
• LEVINE MM, TACKET CO,SZTEIN MB: Host-Salmonella interaction: human trials. Microbes Infect. (2001) 3(14-15):1271–1279.
   PubMed Web of Science ®Google Scholar
• WAHDAN MH, SERIE C, CERISIER Y, SALLAM S, GERMANIER R: A controlled field trial of live Salmonella Ophistrain Ty 21a oral vaccine against typhoid: three-year results. J. Infect. Dis. (1982) 145(3):292–295.
   PubMed Web of Science ®Google Scholar
• LEVINE MM, FERRECCIO C,BLACK RE, GERMANIER R: Large-scale field trial of Ty2la, a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet (1987) 1:1049–1052.
   PubMed Web of Science ®Google Scholar
• BLACK RE, LEVINE MM,FERRECCIO C et al: Efficacy of one or two doses of Ty2la Salmonella typhivaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine (1990) 8(1):81–84.
   PubMed Web of Science ®Google Scholar
• FERRECCIO C, LEVINE MM, RODRIGUEZ H, CONTRERAS R: Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J. Infect. Dis. (1989) 159(4):766–769.
   PubMed Web of Science ®Google Scholar
• LEVINE M, FERRECCIO C,CRYZ SJ JR, ORTIZ E: Comparison of enteric-coated capsules and liquid formulation of Ty2la typhoid vaccine in a randomized controlled field trial. Lancet (1990) 336:891–894.
   PubMed Web of Science ®Google Scholar
• •Randomised controlled trial with Ty2la vaccine in Chile.
   Google Scholar
• SIMANJUNTAK CH, PALEOLOGO FP, PUNJABI NH et al.: Oral immunisationagainst typhoid fever in Indonesia with Ty2la vaccine. Lancet (1991) 338(8774):1055–1059.Randomised controlled trial with Ty2la vaccine in Indonesia.
   Google Scholar
• LEVINE MM, FERRECCIO C, BLACK RE, TACKET CO, GERMANIER R: Progress in vaccines against typhoid fever. Rev Infect. Dis. (1989) 11\(Suppl. 3):5552–5567.
   Google Scholar
• LEVINE MM, BLACK RE,FERRECCIO C et al: The efficacy of attenuated Salmonella Ophi oral vaccine strain Ty2la evaluated in controlled field trials. In: Development of Vaccines and Drugs Against Diarrhea. 11th Noble Conference, Stockholm, 1985. Holmgren J, Lindberg A, Möllby R (Eds), Studentlitteratur, Lund, Sweden (1986):90–101.
   Google Scholar
• BLACK R, LEVINE MM, YOUNG C et al.: Immunogenicity of Ty2 la attenuated Salmonella Ophl given with sodium bicarbonate or in enteric-coated capsules. Dev. Biol. Stand (1983) 53:9–14.
   PubMedGoogle Scholar
• LINDBERG AA: Glycoprotein conjugate vaccines. Vaccine (1999) 17\(Suppl. 2):528–536.
   Google Scholar
• SZU SC, TAYLOR DN, TROFA AC et al: Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect. Immun. (1994) 62(10):4440–4444.
   PubMed Web of Science ®Google Scholar
• LIN FY, HO VA, KHIEM HB et al.: The efficacy of a Salmonella Ophi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. (2001) 344(17):1263–1269.
   PubMed Web of Science ®Google Scholar
• MAI NL, PHAN VB, VO AH et al: Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. (2003) 349 (14):1390–1391.
   PubMed Web of Science ®Google Scholar
• •Four-year protective effect of the first Vi conjugate vaccine.
   Google Scholar
• GARMORY HS, BROWN KA,TITBALL RW: Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev (2002) 26(4)339–353.
   Google Scholar
• •An updated review of S. Typhi strains for vaccine candidates.
   Google Scholar
• TACKET CO, SZTEIN MB,WASSERMAN SS et al.: Phase II clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908- htrA in US volunteers. Infect. Immun. (2000) 68:1196–1201.
   Google Scholar
• TACKET CO, PASETTI ME SZTEIN MB, LIVIO S, LEVINE MM: Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J. Infect. Dis. (2004) 190(3):565–570.
   PubMed Web of Science ®Google Scholar
• HOHMANN EL, OLETTA CA, KILLEEN KP, MILLER SI: phoP/phoQ-deleted Salmonella hphi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. Infect. Dis. (1996) 173(6):1408–1414.
   Google Scholar
• TACKET CO, KELLY SM, SCHODEL F et al.: Safety and immunogenicity in humans of an attenuated Salmonella typhi vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the asd-balanced lethal vector system.Infect. Inman. (1997) 65:3381–3385.
   PubMed Web of Science ®Google Scholar
• HINDLE Z, CHATFIELD SN, PILLIMORE J, BENTLEY M, JOHNSON J, COS GROVE CA: Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Inman. (2002) 70:3457–3467.
   PubMed Web of Science ®Google Scholar
• KOTLOFF KL, WINICKOFF JP, IVANOFF B et al.: Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. (1999) 77(8):651–666.
   PubMed Web of Science ®Google Scholar
• ••A definitive review of the global burdenof shigellosis.
   Google Scholar
• THIEM V, SETHABUTR 0,VON SEIDLEIN L et al.: Is shigellosis even more widespread than previously thought? IpaH detection in Nha Trang, Vietnam.Gin. Microbial. (2004) (In Press).
   Google Scholar
• BENNISH ML, HARRIS JR,WOJTYNIAK BJ, STRUELENS M: Death in shigellosis: incidence and risk factors in hospitalized patients. .I. Infect. Dis. (1990) 161(3):500–506.
   PubMed Web of Science ®Google Scholar
• BENNISH ML: Potentially lethal complications of shigellosis. Rev Infect. D (1991) 13\(Suppl. 4):319–324.
   Google Scholar
• THORPE CM, SMITH WE,HURLEY BP, ACHESON DW: Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression.Infect. Inman. (2001) 69(10):6140–6147.
   Google Scholar
• LINDBERG AA, HAEGGMAN S, KARLSSON K, PHUNG DC, DANG DT: The humoral antibody response to Shigella dysenteriae type 1 infection, as determined by ELISA. Bull. World Health Organ. (1984) 62(4):597–606.
   PubMed Web of Science ®Google Scholar
• SZU S, ROBBINS JB, SCHNEERSON R, POZGAY V, CHU C: Polysaccharide-based conjugate vaccines for enteric bacterial infections: typhoid fever, notypoidal salmonellosis, shigellosis, cholera, Escherichia coil 0157. In: New Generation Vaccines. Levine MM (Ed), Marcel Dekker, NY, USA (2004):471–478.
   Google Scholar
• ••An excellent review of conjugate vaccinesto protect against enteric organisms.
   Google Scholar
• TALUKDER KA, DUTTA DK, SAFA A et al: Altering trends in the dominance of Shigella flexneri serotypes and emergence of serologically atypical S. flexneri strains in Dhaka, Bangladesh. I Gin. Microbial. (2001) 39(10):3757–3759.
   Google Scholar
• TALUKDER KA, ISLAM MA, DUTTA DK et al: Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh. J. Gin. Microbial. (2002) 40(7):2490–2497.
   Web of Science ®Google Scholar
• TALUKDER KA, ISLAM Z, ISLAM MA et al: Phenotypic and genotypic characterization of provisional serotype Shigella flexneri 1c and clonal relationships with la and lb strains isolated in Bangladesh. J. Clin. Microbial. (2003) 41(1):110–117.
   PubMed Web of Science ®Google Scholar
• MEL DM, TERZIN AL, VUKSIC L: Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull. World Health Organ. (1965) 32(5):647–655.
   Google Scholar
• KOTLOFF KL, NATARO JP,LOSONSKY GA et al.: A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine (1995) 13(16):1488–1494.
   Google Scholar
• FERRECCIO C, PRADO V, OJEDA A, CAYYAZO M, ABREGO P, GUERS L et al.: Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemia (1991) 134(6):614–627.
   PubMed Web of Science ®Google Scholar
• FORMAL SB, KENT TH, MAY HC, PALMER A, FALKOW S, LABREC EH: Protection of monkeys against experimentalshigellosis with a living attenuated oral polyvalent dysentery vaccine. J. Bacteria (1966) 92(1):17–22.
   PubMed Web of Science ®Google Scholar
• MEL DM, TERZIN AL, VUKSIC L: Studies on vaccination against bacillary dysentery. 1. Immunization of mice against experimental Shigella infection. Bull. World Health Organ. (1965) 32(5):633–636.
   Google Scholar
• MEL D, STANKOVIC N: Study on the streptomycin-dependent Shigella flexneri strain for oral vaccination against dysentery. Vanosanit. Pregl. (1965) 22(6):381–387.
   PubMedGoogle Scholar
• MEL DM, PAPO RG, TERZIN AL, VUKSIC L: Studies on vaccination against bacillary dysentery. 2. Safety tests and reactogenicity studies on a live dysentery vaccine intended for use in field trials. Bull. World Health Organ. (1965) 32(5):637–645.
   Google Scholar
• MEL DM, ARSIC BL, NIKOLIC BD, RADOVANIC ML: Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull. World Health Organ. (1968) 39(3):375–380.
   Google Scholar
• MEL DM, CVJETANOVIC B, FELSENFELD 0: Studies on vaccination against bacillary dysentery. 5. Studies inErythrocebus patas. Bull. World Health Organ. (1970) 43(3):431–437.
   Google Scholar
• MEL D, GANGAROSA EJ, RADOVANOVIC ML, ARSIC BL, LITVINJENKO S: Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull. World Health Organ. (1971) 45(4):457–464.
   Google Scholar
• MEL DM, ARSIC BL,RADOVANOVIC ML,LIT VINJENKO SA: Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbia Acad. Sci. Hung (1974) 21(1-2):109–114.
   PubMedGoogle Scholar
• ISTRATI G, ISTRATI M, MEITERT T,CIUFECO C: Genetic stability of the non-pathogenic and anti-infectious immunogenic character of some strains ofSh. flexneri 2a. Arch. Roum. AthaExp. Microbia (1965) 24(4):867–874.
   Google Scholar
• MEITERT T, PENCU E, CIUDIN L, TONCIU M: Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch. Roum. Pathol Exp. Microbia (1984) 43(3–4):251-278.Expert Op/n. Biol. Ther. (2004) 4(12)
   Google Scholar
• TUG, CUT C, WANG J etal.: Double-blind field trial of oral live F2a-Sonnei (FS) dysentery vaccine. J. Biol. Prod. (1999) 12(3):178–180.
   Google Scholar
• COSTER TS, HOGE CW, VANDEVERG LL et al.: Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Inman. (1999) 67(7):3437–3443.
   PubMed Web of Science ®Google Scholar
• KATZ DE, COSTER TS, WOLF MK et al.: Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect. Inman. (2004) 72(2):923–930.
   PubMed Web of Science ®Google Scholar
• KOTLOFF K, BARREY E, HALE T, SANSONETTI PJ: Overview of live vaccine strategies against Shigella. In: New Generation Vaccines. Levine MM (Ed), Marcel Dekker, NY, USA (2004):723–735.
   Google Scholar
• ••An excellent in-depth review ofshigellosis vaccines.
   Google Scholar
• HARTMAN AB, VENKATESAN MM: Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Lifect. Inman. (1998) 66(9):4572–4576.
   PubMed Web of Science ®Google Scholar
• KOTLOFF KL, TAYLOR DN,SZTEIN MB et al.: Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Inman. (2002) 70 (4) :2016–2021.
   Google Scholar
• NORIEGA FR, LOSONSKY G, LAUDERBAUGH C, LIAO FM,WANG JY, LEVINE MM: Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine. Infect. Inman. (1996) 64(8):3055–3061.
   PubMed Web of Science ®Google Scholar
• NORIEGA FR, LOSONSKY G, WANG JY, FORMAL SB, LEVINE MM: Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coil.Infect. Inman. (1996) 64(1):23–27.
   Google Scholar
• KOTLOFF KL, NORIEGA FR, SAMANDARI T et al.: Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Inman. (2000) 68(3):1034–1039.
   PubMed Web of Science ®Google Scholar
• BARREY E, LEVINE MM: Multivalent Shigella/enterotoxigenic Escherichia coil vaccine. In: New Generation Vaccines. Levine MM (Ed), Marcel Dekker, NY, USA (2004):751–754.
   Google Scholar
• NORIEGA FR, LIAO FM,MANEVAL DR, REN S, FORMAL SB, LEVINE MM: Strategy for cross-protection among Shigella flexneri serotypes.Infect. Inman. (1999) 67(2):782–788.
   Google Scholar
• ROBBINS JB, SCHNEERSON R, ANDERSON P, SMITH DH: The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA (1996) 276(14):1181–1185.
   Google Scholar
• TAYLOR DN, TROFA AC, SADOFF J et al.: Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the 0-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Inman. (1993) 61(9):3678–3687.
   PubMed Web of Science ®Google Scholar
• COHEN D, ASHKENAZI S, GREEN MS et al.: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet (1997) 349(9046):155–159.
   PubMed Web of Science ®Google Scholar
• •Randomised controlled trial that showed protection against shigellosis by a conjugate vaccine.
   Google Scholar
• POZSGAY V, CHU C, PANNELL L, WOLFE J, ROBBINS JB, SCHNEERSON R: Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the 0-specific polysaccharide from Shigella dysenteriae type 1. Proc. Nati Acad. Sci. USA (1999) 96(9):5194–5197.
   PubMed Web of Science ®Google Scholar
• XU DQ, CISAR JO, AMBULOS JN JR, BURR DH, KOPECKO DJ: Molecular cloning and characterization of genes for Shigella sonnei form I 0 polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector. Infect. Inman. (2002) 70(8):4414–4423.
   PubMed Web of Science ®Google Scholar
• GUSTAFSON GL, GANDER JE: 0 beta-(N-acetyl-alpha-glucosamine-1-phosphoryl)serine in proteinase I fromDictyostelium discoideum. Methods Enzyma (1984) 107:172–183.
   PubMed Web of Science ®Google Scholar
• EMSLIE KR, SLADE MB,WILLIAMS KL: From virus to vaccine: developments using the simple eukaryote,DicOvstelium discoideum. Trends Microbia (1995) 3(12):476–479.
   PubMed Web of Science ®Google Scholar
• YOUMANS AS, YOUMANS GP: Preparation and effect of different adjuvants on the immunogenic activity of mycobacterial ribosomal fraction. J. Bacteria (1967) 94(4):836–843.
   PubMed Web of Science ®Google Scholar
• LEVENSON VI, SUBBOTINA IUL, GOFMAN IL, IAROVAIA LM: Ribosomal dysentery vaccine. I. Method of production, physical and chemical properties.Zh. Mikrobia Epidemia Immunobia (1978) (3):60–65.
   Google Scholar
• LEVENSON VI, BELKIN ZP, EGOROVA TP, LIUBINSKAIA MM, SAZYKINA S: The immunogenic and serological properties of the 0-specific polysaccharide (L-hapten) in Shigella.Zh. Mikrobia Epidemia Immunobia (1991) (7):25–29.
   Google Scholar
• LEVENSON VJ, EGOROVA TP: Effective stimulation of the mucosal immune response by parenteral vaccination with weak antigen associated with a nucleoprotein vehicle. Ann. NY Acad. Sci. (1994) 730:353–355.
   PubMed Web of Science ®Google Scholar
• LEVENSON VJ, MALLETT CP, HALE TL: Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect. Inman. (1995) 63(7):2762–2765.
   PubMed Web of Science ®Google Scholar
• ORR N, ROBIN G, COHEN D, ARNON R, LOWELL GH: Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Inman. (1993) 61(6):2390–2395.
   PubMed Web of Science ®Google Scholar
• FRIES LF, MONTEMARANO AD, MALLETT CP, TAYLOR DN, HALE TL, LOWELL GH: Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.Infect. Inman. (2001) 69(7)4545–4553.
   Google Scholar
• WANG JY, NORIEGA FR, GALEN JE, BARRY E, LEVINE MM: Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909. Infect. Immun. (2000) 68(8):4647–4652.
   PubMed Web of Science ®Google Scholar